HRP20090434T1 - Sastavi kontroliranog otpuštanja za interferon koji se temelji na pegt/pbt blok kopolimerima - Google Patents

Sastavi kontroliranog otpuštanja za interferon koji se temelji na pegt/pbt blok kopolimerima Download PDF

Info

Publication number
HRP20090434T1
HRP20090434T1 HR20090434T HRP20090434T HRP20090434T1 HR P20090434 T1 HRP20090434 T1 HR P20090434T1 HR 20090434 T HR20090434 T HR 20090434T HR P20090434 T HRP20090434 T HR P20090434T HR P20090434 T1 HRP20090434 T1 HR P20090434T1
Authority
HR
Croatia
Prior art keywords
block copolymers
composition
pegt
poly
controlled release
Prior art date
Application number
HR20090434T
Other languages
English (en)
Croatian (hr)
Inventor
Chantal Bechet Anne
Van Dijkhuizen-Radersma Riemke
Stigter Martin
Mattijs Bezemer Jeroen
Original Assignee
Biolex Therapeutics
Octoplus Polyactive Sciences B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolex Therapeutics, Octoplus Polyactive Sciences B.V. filed Critical Biolex Therapeutics
Publication of HRP20090434T1 publication Critical patent/HRP20090434T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20090434T 2005-01-07 2009-08-11 Sastavi kontroliranog otpuštanja za interferon koji se temelji na pegt/pbt blok kopolimerima HRP20090434T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05075043A EP1679065A1 (en) 2005-01-07 2005-01-07 Controlled release compositions for interferon based on PEGT/PBT block copolymers
PCT/NL2006/000006 WO2006085747A1 (en) 2005-01-07 2006-01-06 Controlled release compositions for interferon based on pegt/pbt block copolymers

Publications (1)

Publication Number Publication Date
HRP20090434T1 true HRP20090434T1 (hr) 2009-09-30

Family

ID=34937981

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090434T HRP20090434T1 (hr) 2005-01-07 2009-08-11 Sastavi kontroliranog otpuštanja za interferon koji se temelji na pegt/pbt blok kopolimerima

Country Status (24)

Country Link
US (3) US7736674B2 (ja)
EP (4) EP1679065A1 (ja)
JP (2) JP2008526837A (ja)
KR (2) KR101354521B1 (ja)
CN (2) CN101137349B (ja)
AT (1) ATE431134T1 (ja)
AU (2) AU2006213168B2 (ja)
BR (1) BRPI0606514A2 (ja)
CA (1) CA2594434A1 (ja)
CY (1) CY1109297T1 (ja)
DE (1) DE602006006797D1 (ja)
DK (1) DK1843749T3 (ja)
ES (1) ES2327267T3 (ja)
HK (1) HK1152644A1 (ja)
HR (1) HRP20090434T1 (ja)
IL (2) IL184431A (ja)
MX (1) MX2007008293A (ja)
PL (1) PL1843749T3 (ja)
PT (1) PT1843749E (ja)
RS (1) RS51129B (ja)
RU (2) RU2409348C2 (ja)
SG (1) SG158856A1 (ja)
SI (1) SI1843749T1 (ja)
WO (1) WO2006085747A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
WO2009015336A2 (en) * 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
JP5733981B2 (ja) 2007-10-23 2015-06-10 コーニンクレッカ フィリップス エヌ ヴェ ポリマー微粒子を調製する方法及びデバイス
EP2055299A1 (en) * 2007-10-23 2009-05-06 Koninklijke Philips Electronics N.V. Methods for preparing polymer microparticles
WO2010001325A2 (en) * 2008-06-30 2010-01-07 Silenseed Ltd Methods, compositions and systems for local delivery of drugs
AU2010220324A1 (en) 2009-03-05 2011-09-01 Ascendis Pharma As Interferon alpha carrier prodrugs
EA201391392A1 (ru) * 2011-03-25 2014-04-30 Селекта Байосайенсиз, Инк. Синтетические наноносители с осмотически опосредованным высвобождением
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2016046817A1 (en) 2014-09-24 2016-03-31 Vital Beverages Global Inc. Compositions and methods for selective gi tract delivery
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2022539602A (ja) 2019-07-12 2022-09-12 ビーエーエスエフ ソシエタス・ヨーロピア 揮発性有機活性剤が充填された微粒子を製造する方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL280825A (ja) * 1962-07-11
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
EP0637229B1 (en) 1992-04-24 2002-11-20 Osteotech, Inc., Devices for preventing tissue adhesion
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
DE69316101T2 (de) * 1992-08-07 1998-10-22 Takeda Chemical Industries Ltd Herstellung von Mikrokapseln, die wasserlösliche Arzneimittel enthalten
US5643605A (en) 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
WO1997020047A1 (en) 1995-11-30 1997-06-05 Board Of Regents, The University Of Texas System Methods and compositions for the diagnosis and treatment of cancer
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
DK0990440T3 (da) 1997-02-27 2009-02-23 Novartis Ag Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid
EP0975334B1 (en) * 1997-04-17 2003-10-22 Amgen Inc., Biodegradable microparticles for the sustained delivery of therapeutic drugs
TW577759B (en) 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation
US6531154B1 (en) 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
HUP0004169A3 (en) * 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
CA2360232A1 (en) * 1999-01-12 2000-07-20 Tamio Mizukami Telomerase inhibitors
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
US20030206928A1 (en) * 1999-04-07 2003-11-06 Pertti Tormala Bioactive, bioabsorbable surgical polyethylene glycol and polybutylene terephtalate copolymer composites and devices
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
AU5853000A (en) 1999-07-15 2001-02-05 Takeda Chemical Industries Ltd. Sustained release compositions, process for producing the same and use thereof
EP1090928B1 (en) 1999-09-30 2004-05-26 Chienna B.V. Polymers loaded with bioactive agents
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
JP4557409B2 (ja) * 2000-11-13 2010-10-06 日東電工株式会社 多孔質ポリイミドの製造方法及び多孔質ポリイミド
EP1341522B1 (de) 2000-12-13 2005-11-16 Merckle Gmbh Mikropartikel mit verbessertem freisetzungsprofil und verfahren zu deren herstellung
US8637077B2 (en) 2000-12-28 2014-01-28 Takeda Pharmaceutical Company Limited Sustained-release preparation
RU2191012C1 (ru) 2001-06-20 2002-10-20 Научно-исследовательский испытательный центр (медико-биологической защиты) Государственного научно-исследовательского испытательного института военной медицины МО РФ Глазные капли для лечения эндотелиально-эпителиальной дистрофии роговицы
WO2003035030A1 (en) 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
WO2003041689A1 (en) * 2001-11-12 2003-05-22 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
TWI252111B (en) 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
KR100994658B1 (ko) 2001-12-26 2010-11-16 다케다 야쿠힌 고교 가부시키가이샤 신규 마이크로스피어 및 이들의 제조 방법
ES2605402T3 (es) 2002-06-25 2017-03-14 Takeda Pharmaceutical Company Limited Procedimiento para producir una composición de liberación sostenida
US8871269B2 (en) 2003-07-15 2014-10-28 Evonik Corporation Method for the preparation of controlled release formulations
EP2409707B8 (en) 2004-04-15 2015-05-06 Alkermes Pharma Ireland Limited Polymer-based sustained release device
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers

Also Published As

Publication number Publication date
CN101137349A (zh) 2008-03-05
AU2010224413A1 (en) 2010-10-14
AU2006213168B2 (en) 2011-09-15
US20080008733A1 (en) 2008-01-10
EP1886668A1 (en) 2008-02-13
CA2594434A1 (en) 2006-08-17
PT1843749E (pt) 2009-08-17
RS51129B (sr) 2010-10-31
EP2266535A3 (en) 2011-06-15
KR20100109983A (ko) 2010-10-11
RU2007130090A (ru) 2009-02-20
RU2409348C2 (ru) 2011-01-20
CN101137349B (zh) 2013-01-02
IL208175A0 (en) 2010-12-30
HK1152644A1 (en) 2012-03-09
JP2008526837A (ja) 2008-07-24
EP1843749A1 (en) 2007-10-17
RU2010138739A (ru) 2012-03-27
CY1109297T1 (el) 2014-07-02
SG158856A1 (en) 2010-02-26
EP2266535B1 (en) 2013-03-06
BRPI0606514A2 (pt) 2010-01-19
US7867518B2 (en) 2011-01-11
ATE431134T1 (de) 2009-05-15
IL184431A (en) 2012-03-29
US20100074868A1 (en) 2010-03-25
US8163307B2 (en) 2012-04-24
WO2006085747A1 (en) 2006-08-17
EP1886668B1 (en) 2012-11-14
AU2006213168A1 (en) 2006-08-17
PL1843749T3 (pl) 2009-10-30
KR101354521B1 (ko) 2014-01-22
EP1843749B1 (en) 2009-05-13
KR20070118225A (ko) 2007-12-14
CN101791396A (zh) 2010-08-04
SI1843749T1 (sl) 2009-10-31
EP1679065A1 (en) 2006-07-12
JP4887542B2 (ja) 2012-02-29
EP2266535A2 (en) 2010-12-29
MX2007008293A (es) 2007-12-07
DK1843749T3 (da) 2009-09-07
IL184431A0 (en) 2007-10-31
US20090226532A1 (en) 2009-09-10
AU2010224413B2 (en) 2012-03-22
ES2327267T3 (es) 2009-10-27
US7736674B2 (en) 2010-06-15
JP2011016836A (ja) 2011-01-27
DE602006006797D1 (de) 2009-06-25

Similar Documents

Publication Publication Date Title
HRP20090434T1 (hr) Sastavi kontroliranog otpuštanja za interferon koji se temelji na pegt/pbt blok kopolimerima
CN102660197B (zh) 一种皮革光亮剂及皮革光亮湿巾
ATE388758T1 (de) Verfahren zum auflösen lipophiler verbindungen, und kosmetische zusammensetzung.
HRP20150272T1 (hr) Oblik s produljenim oslobađanjem na bazi polimera
AR011002A1 (es) Composicion de champu para estilizar el cabello
HRP20131173T4 (hr) Vodeni farmaceutski pripravci koji sadrže boratno-poliolne komplekse
ATE309197T1 (de) Verfahren zur herstellung alkylierter salicylamide
JP2008519589A5 (ja)
BR0008405A (pt) Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
NO20034492L (no) HSA-frie formuleringer av Interferon-<beta>
TR200101446T2 (tr) Koku kontrolü için iyileştirilmiş bileşikleşmemiş siklodekstrin bileşimleri
ME00408B (me) Preparati insulina koji ne sadrže cink ili sadrže male količine cinka koji imaju poboljšanu stabilnost
CO5271726A1 (es) Composicion farmaceutica soluble en agua en un complejo ionico y el uso de la misma
ATE471352T1 (de) Polyamidpulver mit dauerhafter, gleichbleibend guter rieselfähigkeit
JP2004532218A5 (ja)
AR041913A1 (es) Formulaciones de deposito de liberacion controlada
JP2008522981A5 (ja)
BR0010575A (pt) Composição de amaciamento de tecido, e, método de depositar um agente de amaciamento de tecido não iÈnico no tecido de uma composição de amaciamento de tecido
AR021624A1 (es) Composiciones para el lavado
ES2570856T3 (es) Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros
ATE489462T1 (de) Antimikrobielles polypeptid und nutzung davon
AR033243A1 (es) Un antitranspirante y/o desodorante de fases, aplicable a bolilla
BR9914904A (pt) Lentes intraoculares feitas com composições poliméricas
ATE348602T1 (de) Nanoteilchen zur verabreichung von wirkstoffen, verfahren zur herstellung dieser teilchen und diese enthaltende zusammensetzung
JP2005533081A5 (ja)